GOVX: Lead programs advanced and net loss narrowed as focus shifted away from COVID-19 vaccine
Q2 2026 saw continued advancement of lead vaccine and immuno-oncology programs, with a narrowed focus following the discontinuation of COVID-19 vaccine development. Net loss narrowed year-over-year, and cash position remained stable as the company prepares for a pivotal clinical trial.Original docu…